Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03670017
Other study ID # GIDE Study
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 6, 2018
Est. completion date September 4, 2020

Study information

Verified date September 2021
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate patients requiring frequent glucose monitoring in a Surgical ICU. The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device [i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed.


Description:

Hyperglycemia, hypoglycemia and glycemic variability are independently associated with morbidity and mortality of critically ill patients. Blood glucose control with insulin has the potential to decrease morbidity and mortality of intensive care unit (ICU) patients. Blood glucose control with insulin, however, is associated with an increased risk of hypoglycemia and may not decrease glycemic variability. In addition, blood glucose control with insulin utilizing manual systems for glucose measurement is blood-consuming and time-consuming, since frequent blood draws for glucose measurements are necessary in order to achieve blood glucose control. Automated, frequent, plasma-based glucose monitoring with the OptiScanner 5000 glucose monitoring system has the potential to improve a patient's glucose TIR by improving all 3 domains of glycemic control: reducing hyperglycemia while at the same time preventing hypoglycemia and reducing glycemic variability. Second, it could reduce the workloads associated with the high number of blood samples to be obtained and analyzed. The primary objective of this study is to observe the Time-in-Range for patients whose glycemic control is being monitored with the OptiScanner system. A secondary objective is assessment of the time it takes the patient to achieve in range glucose values while connected to the OptiScanner. The study will evaluate patients requiring frequent glucose monitoring in a Surgical ICU. The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device [i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed. Currently glucose values are measured using point of care glucose meters and/or by collecting a blood sample and sending it to the hospital laboratory. Patients' glucose values are currently monitored depending on their clinical condition with the frequency of glucose measurement typically occurring every one to four hours. Patients enrolled in this study will still be monitored in this same manner, depending on their clinical condition (using point of care meters and/or blood collection for the lab). The additional continuous monitoring provided by the OptiScanner may introduce additional glucose measurements. The clinical care team will be advised to confirm any OptiScanner glucose value (using routine clinical care methods) before making any modifications to the patient's clinical care based on the OptiScanner result (i.e. increase, decrease, stop insulin drip, etc.). A research team member will be at the bedside during the patients' connection to the OptiScanner to ensure that the clinical team does not use the OptiScanner results to direct patient care and to observe the overall clinical care glucose management of the patient. Clinical data will be captured on the participants.


Recruitment information / eligibility

Status Terminated
Enrollment 68
Est. completion date September 4, 2020
Est. primary completion date September 4, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria 1. Signed informed consent by the participant or his/her legally authorized representative; 2. At least 18 years old; 3. Admitted to a Surgical Intensive Care Unit (SICU) or planned admission to a Surgical ICU at time of screening 4. Expected SICU stay of at least 48 hours at the time of enrollment 5. A vascular access device available for connection to the OptiScanner is either already in-place, or is planned to be placed with an expected usage of at least 48 hours. Exclusion Criteria 1. Positive Human chorionic gonadotropin (HcG) (serum or urine ) in women of childbearing potential (age < 60) who are not known to be surgically sterile and those that are obviously pregnant. 2. Patients undergoing peritoneal dialysis within the past week. 3. Patients actively receiving intravenous immunoglobulin therapy. 4. Patients receiving intravenous administration of high dose ascorbate (IVC) for the treatment of patients with cancer. 5. Patients following the administration of a D-Xylose absorption test < 12 hours 6. Patients being treated with Sodium Thiosulfate 7. Patients being receiving IV glycerol 8. Patients receiving substances containing maltose, or substances that can be metabolized into maltose. These substances include Extraneal, Gamimune N, HepaGam B, Octagam, Vaccinia Immune Globulin, and WinRho SDF Liquid. 9. Hct <15% within 24 hours of screening visit

Study Design


Related Conditions & MeSH terms


Intervention

Device:
OptiScanner® 5000 Glucose Monitoring System
The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device [i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed.

Locations

Country Name City State
United States Barnes Jewish Hospital Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine OptiScan Biomedical Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glucose Time-in-range (TIR) Glucose time in range will be defined by participant's clinical care defined target glucose range Up to 72 hours
Secondary Assessment of the Time it Takes the Patient to Achieve in Range Glucose Values While Connected to the OptiScanner. Evaluation of the amount of time required for a patient to have in range glucose values Up to 72 hours
See also
  Status Clinical Trial Phase
Recruiting NCT03306810 - Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service N/A
Recruiting NCT06019910 - Snus and Home Blood Pressure N/A
Active, not recruiting NCT01605422 - Meta-analyses of the Effect of Dietary Pulses on Acute Postprandial Metabolic Control N/A
Completed NCT04107987 - Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients With Fasting Dysglycemia Phase 3
Completed NCT04107922 - Nutraceutical on Hyperglycemia Phase 3
Recruiting NCT06348550 - Effect of the Association of Berberine Fitosoma® and Monacolin K MonaKoPure® on Glyco-metabolic Parameters in Dysglycemic and Dyslipidemic Patients. N/A
Recruiting NCT06050265 - Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome N/A
Not yet recruiting NCT02960373 - Dried Fruit and Postprandial Glycemia Trial N/A
Completed NCT03299205 - Alcohol & Metabolic Comorbidities in PLWHA: Evidence Driven Interventions N/A
Active, not recruiting NCT05191160 - The Soy Treatment Evaluation for Metabolic Health (STEM) Trial N/A
Recruiting NCT05852054 - Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP) Phase 3
Active, not recruiting NCT04767672 - Study to Assess the Effects of Non Digestible Carbohydrates on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects N/A
Completed NCT03543644 - Strategies To OPpose Sugars With Non-nutritive Sweeteners Or Water (STOP Sugars NOW) Trial N/A
Recruiting NCT05277558 - Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
Completed NCT04525508 - Coronary Artery Plaque Burden in Asymptomatic Danish Men Aged 65-75 Years and the Relation to Glycemic Status.
Active, not recruiting NCT02037321 - Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk N/A
Active, not recruiting NCT01608620 - Meta-analyses of Fructose-containing Sugars and Incident Cardiometabolic Disease N/A
Active, not recruiting NCT01608607 - Meta-analysis of Fructose-Containing Sugar Sweetened Beverages (SSBs) and Weight Change N/A
Completed NCT01630980 - Meta-analyses of the Effect of Tree Nuts on Glycemic Control and Features of the Metabolic Syndrome N/A
Active, not recruiting NCT01363791 - Meta-analyses of Fructose and Cardiometabolic Risk N/A